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Abstract
Background: Pregnancy is associated with reduced activity of multiple sclerosis (MS). However, the biological mechanisms
underlying this pregnancy-related decrease in disease activity are poorly understood.
Methodology: We conducted a genome-wide transcription analysis in peripheral blood mononuclear cells (PBMCs) from 12
women (7 MS patients and 5 healthy controls) followed during their pregnancy. Samples were obtained before, during (i.e.
at the third, sixth, and ninth month of gestation) and after pregnancy. A validation of the expression profiles has been
conducted by using the same samples and an independent group of 25 MS patients and 11 healthy controls. Finally,
considering the total group of 32 MS patients, we compared expression profiles of patients relapsing during pregnancy
(n=6) with those of relapse-free patients (n=26).
Principal Findings: Results showed an altered expression of 347 transcripts in non-pregnant MS patients with respect to
non-pregnant healthy controls. Complementary changes in expression, occurring during pregnancy, reverted the previous
imbalance particularly for seven inflammation-related transcripts, i.e. SOCS2, TNFAIP3, NR4A2, CXCR4, POLR2J, FAM49B, and
STAG3L1. Longitudinal analysis showed that the overall deregulation of gene expression reverted to ‘‘normal’’ already
within the third month of gestation, while in the post-partum gene expressions rebounded to pre-pregnancy levels. Six
(18.7%) of the 32 MS patients had a relapse during pregnancy, mostly in the first trimester. The latter showed delayed
expression profiles when compared to relapse-free patients: in these patients expression imbalance was reverted later in the
pregnancy, i.e. at sixth month.
Conclusions: Specific changes in expression during pregnancy were associated with a decrease in disease activity assessed
by occurrence of relapses during pregnancy. Findings might help in understanding the pathogenesis of MS and may
provide basis for the development of novel therapeutic strategies.
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Introduction
Pregnancy represents a physiological transitory state of immune
tolerance to avoid the rejection of the fetus, and is frequently
associated with reduced activity of autoimmune diseases, including
multiple sclerosis (MS). Natural course studies in MS have shown
that the relapse rate during pregnancy, especially in the third
trimester, decreases more than under treatment with currently
approved first line treatments interferon-beta or glatiramer
acetate. During the first three months post-partum an increase
of the relapse rate follows before returning to the pre-pregnancy
rate [1–3]. In general, the lower relapse rate during pregnancy
might be due to a pregnancy-associated down-regulation of cell-
mediated immunity.
While the etiology of MS is unknown, autoreactive Th1/Th17
cells are thought to play an essential role in the pathogenesis of the
disease [4–5]. On the contrary, pregnancy results in a shift towards
Th2 cytokine profile [6]. Thus, the protective effect of pregnancy
in MS might be explained by the antagonistic effects of Th2
response, which inhibit the development of both pro-inflammatory
Th1 and Th17 cells [7].
The whole balance among Th1, Th2, and Th17 is regulated by
a specific subpopulation of T-lymphocytes, e.g. CD4
+CD25
+
regulatory T-cells (Treg), which are activated to modulate immune
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8962responses to avoid over-reactive immunity [7]. Recently, an
increase in CD4
+CD25
+Treg has been described in humans during
pregnancy [8,9]. Hence, systemic expansion of CD4
+CD25
+ T-
lymphocytes may add on the concept of immune system pregnant-
related suppression and might support the better clinical MS
pregnancy course.
A variety of pregnancy-factors can be involved in this immune
shift, including sex hormones [10–12], which appear to be
involved in regulating the immune response [13]. Estrogens,
indeed, are known to exert opposing, bimodal, dose-specific effect
to immune response: low levels facilitate a cell-mediated pro-
inflammatory immune response, whereas their relatively high
levels, such as those achieved during pregnancy, promote anti-
inflammatory Th2 responses.
Collectively, the protective effect of pregnancy in MS and the
anti-inflammatory effects of estrogens have suggested that
hormones associated with pregnancy may exert the beneficial
influence on MS. Accordingly, a pilot clinical trial using oral estriol
to treat MS patients showed significantly decreased gadolinium
enhancing lesions on monthly cerebral MRI [14].
As a whole, however, no one has until now used a molecular
large-scale approach to study the pregnancy phenomenon in MS
and thus still little is known about the molecular mechanisms
behind the adaptive molecular processes of pregnancy. In the
present study we aim to use modern high-throughput microarray
technology to analyze gene expression profiles during pregnancy
in MS patients and compare them to those in healthy pregnant
volunteers. We seek to determine the MS-associated genes, which
modify their status during pregnancy as a consequence of either
changes in expression in the peripheral blood mononuclear cells
(PBMCs) or changes in cell composition in the PBMC populations
during pregnancy. Such elements will improve the understanding
of protective mechanisms in the maternal immunology of
pregnancy, as related to the pathogenesis of MS, potentially
leading to the development of novel therapeutic strategies for
MS.
Methods
Ethic Statements
This study was approved by the Ethical Committee of the San
Luigi University Hospital (March 2006, approval nu87), and the
research was conducted in accordance with the Declaration of
Helsinki. All subjects with a desire to become pregnant were
potentially included in the study and informed, written consent
was obtained from each of them.
Patients and Controls
In patients with a desire to become pregnant, all disease
modifying treatments (DMTs) were withdrawn for at least three
months before actively trying to become pregnant. Three women
who had an abortion in the first trimester were excluded, while
two patients were excluded because they were not clinical
homogeneous with the remaining patients: one had a clinical
isolated syndrome (CIS) and one had a severe iron deficiency
anemia concurrent to MS. Finally, a consecutive sample of 32
patients with clinically definite relapsing-remitting MS [15] was
enrolled.
Twenty-one age-matched healthy women were included as
controls: 16 of them became pregnant. Pre-pregnancy samples
from all of these healthy women were analyzed for gene
expression.
Demographic and clinical characteristics of healthy controls and
MS patients at baseline are shown in table 1 and table 2.
Study Design
The subjects were followed in the outpatient’s clinic and blood
was collected before pregnancy and at the following time points
during pregnancy: first trimester (gestational age at sampling 1261
weeks), second trimester (gestational age at sampling 2461 weeks),
and third trimester (gestational age at sampling 3661 weeks). Post-
partum blood samples were collected in 28 of the 32 MS patients,
mostly (25/28) between 3 weeks and 4 months after delivery. In
two patients blood was collected 8 months after delivery, and in
one patient the post-partum blood sample was obtained 10 months
after delivery. Likewise, post-partum blood samples were collected
in 14 of the 16 healthy controls, mostly (13/14) between 3 weeks
and 4 months after delivery. In one healthy control blood was
collected 6 months after delivery. Before-pregnancy samples were
obtained from both groups after contraceptive drug withdrawal;
similarly, both before- and after-pregnancy samples were obtained
from MS patients in a DMTs-free period.
PBMCs obtained from 12 women (7 MS patients +5 healthy
controls) were analyzed by oligonucleotide microarray technology.
Microarray findings were then corroborated and extended by real
time RT-PCR in the same cohorts of subjects, as well as in an
independent group of 25 MS patients and 11 healthy controls.
Total RNA and Protein Extraction
PBMCs were isolated from whole blood by centrifugation over
Lymphoprep
TM (Axis-Shield, Oslo, Norway); total RNA and
protein were extracted with TriReagentH following the manufac-
turer’s instruction (Ambion, Austin, TX). RNA and proteins were
stored at 280uC until used.
Microarray Analysis
Double strand cDNA was synthesized from one mg of total RNA
using a cDNA Synthesis System (InvitroGen, Basel, Switzerland)
with the T7-(T)24 primer. The in vitro-labeling kit (Enzo; Farm-
ingdale, NY) was used to transcribe the cDNA into cRNA in the
presence of Biotin-11-CTP and Biotin-16-UTP, according to the
kit instructions. After purification with the MinElute kit (Qiagen;
Hilden, Germany) integrity of the cRNA was assessed by both gel
electrophoresis and BioAnalyzer (Agilent Technologies, Palo Alto,
CA). Twelve mg fragmented cRNA was then used for hybridiza-
tion to the Human Genome U133A 2.0 array (Affymetrix; Santa
Clara, CA). The array contains 21722 probe sets corresponding to
approximately 14564 transcripts. Hybridization and staining were
performed as described previously [16,17].
Real Time RT-PCR
Total RNA (10 ng/mL) was reverse transcribed using random
hexamer primers with the High Capacity cDNA Kit (Applied
Table 1. Demographic characteristics of the 48 pregnant
women.
Category Subcategory MS patients Healthy Controls
No. of women 32 16
Age at the
beginning of
pregnancy (yrs.)
33.1964.15 31.9563.88
Months at
delivery
,9 months 2 1
9 months 30 15
doi:10.1371/journal.pone.0008962.t001
Pregnancy in MS
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real time RT-PCR analysis based on the 59-nuclease assay, with
the ABI PRISMH 7000 Sequence Detection System. For primers
and probes, Applied Biosystems’ TaqManH gene expression assays
were used. Transcriptional expression was normalized using the
housekeeping gene glyceraldehyde-phosphate-dehydrogenase
(GAPDH) as reference, in order to avoid differences due to
possible RNA degradation/contamination or different reverse
transcription efficiencies. Relative expression levels of targets were
calculated by the comparative cycle threshold (Ct) method outlined
in user bulletin no. 2 provided by Applied Biosystems.
Western Blotting
Equal amounts of TriReagentH extracted proteins (20 mg) were
separated electrically on 10% SDS–PAGE gel electrophoresis.
The gels were electrophoresed, followed by a transfer of the
protein to a nitrocellulose membrane. The membrane was then
blocked with a blocking solution and probed with primary
antibodies overnight at 4uC. The primary antibodies and
concentrations used in western blot analysis were as follows:
CxCR4 (1:500, ab2074, Abcam, Cambridge, UK), SOCS2 (1:100,
ab3692, Abcam, Cambridge, UK), and TNFAIP3 (1:200, sc-8432,
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Immunoblots were next processed with appropriate secondary
antibodies (either 1:10000, HRP/goat anti-rabbit IgG, sc-2004, or
1:10000 HRP/goat anti-mouse IgG, sc-2005, both from Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA, based on the
primary antibody) for 1 hour at room temperature. Bands were
detected with a chemiluminescence reagent kit (Western light-
ing
TM Chemiluminescence Reagent Plus, NEL104, Perkin Elmer
LAS Inc., Boston, MA, USA). Blot bands were quantified by
densitometry with Image J software (Image J 1.33u, NIH). b-Actin
(1:1000, sc-8435, Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) was blotted on the same membrane as a loading control for
the protein extract. The data were expressed as relative
densitometric units after background subtraction.
Study Flow-Chart
Since our focus was understanding changes in transcripts
associated to MS and modified during pregnancy, we devised a six
steps analysis based on both microarray and real time RT-PCR
procedures: 1) identification of transcripts associated to MS; 2)
identification of transcripts losing their association to MS in
pregnant patients; 3) validation of the transcripts by real time RT-
PCR; 4) longitudinal analysis during gestation; 5) comparison of
expression profiles of MS patients relapsing during pregnancy with
those of relapse-free patients; 6) confirmation of the gene
expression results on the protein level.
Statistical Analysis
Array analysis. GeneChip Operating Software (GCOS)
(Affymetrix, Santa Clara, CA) was used to generate background-
normalized image data. Microarray quality controls and statistical
validation was done using Bioconductor (www.bioconductor.org)
[18]. The presence of hybridization/construction artifacts was
evaluated with the fitPLM function (Bioconductor package
affyPLM), and the probe (PM) intensity distribution was
evaluated using hist function. Probe set intensities were obtained
by means of RMA (Robust Multichip Average) and normalization
was done according to the quantiles method [19,20]. Probe sets
from all experimental groups were filtered to have an inter-quartile
range for each probe set .0.25 [21]. Subsequently, an intensity
filter, removing all the probe sets characterized by a signal .6.64
in less than 10% of the analyzed arrays, was applied.
Feature selection of transcripts differentially expressed between
MS and healthy specimens was addressed using the so-called rank
product non-parametric method [22]. This method addresses the
multiple comparison problem and performs p-value correction by
false-discovery-rate (FDR), comparing the true rank product
distribution with a random one defined permutating gene labels
in each of the arrays under analysis. Here, we have used 500
permutations and a threshold of percentage of false positive
predictions (pfp) of 0.05. Furthermore, specific pregnancy
signatures were defined for both healthy controls and MS patients
by mean of rank product analysis.
The PAMR method was subsequently used to refine the MS
signature [23]. The subset derived from PAMR analysis was
selected as the best compromise in transcripts number reduction
and low error rate in Leave One-Out Cross-Validation (LOOCV).
PAMR was also used to evaluate the efficacy of the MS signature
during pregnancy, comparing MS and healthy specimens at ninth
month pregnancy.
Table 2. Clinical characteristics of the 32 pregnant women with multiple sclerosis.
Category Subcategory Months
No. of
patients
No. of Relapses
(No. of patients)
EDSS
(median)
Duration of MS before pregnancy 79.54649.61
Before pregnancy (12 mo.) 16 (15) 1.0
Treatment IFNb-1a 30 mgi m 1 1
IFNb-1a 22 mgs c 7
IFNb-1a 44 mgs c 5
IFNb-1b 250 mgs c 3
Glatiramer Acetate 3
No treatment 3
During pregnancy (9 mo.) 1
st trimester 5 (5) 1.0
2
nd trimester 1 (1) 1.0
3
rd trimester 1 (1) 1.0
After Pregnancy (12 mo.) 14 (11) 1.5
doi:10.1371/journal.pone.0008962.t002
Pregnancy in MS
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(ICC) for quantification of the extent to which independent studies
can be reliably analyzed together for the systematic comparison of
microarray profiles [24]. ICC ranges between zero and one; values
closer to one indicate a strong correlation between the two groups.
Here, this approach was used to detect what transcripts most differ
among experimental conditions, i.e. MS patients vs. healthy
controls before pregnancy, and MS patients vs. healthy controls at
ninth month pregnancy. Specifically, all pair-wise correlations
(Pearson coefficient) of gene expression across samples within MS
vs. healthy conditions were calculated and the reproducibility of
the results was defined without relying on direct comparison of
expression across groups.
Microarray data were deposited on GEO database (www.ncbi.
nlm.nih.gov/geo/) as superserie file (GSE17449), encompassing
MS signature, MS pregnancy signature and healthy pregnancy
signature.
Gene annotation and functional analysis was done with IPA 5.0
software (www.ingenuity.com).
Real time RT-PCR analysis. data were analyzed by
parametric statistical tests, using GraphPad PRISM 4.00
(GraphPad Software, San Diego, CA). Expression levels of
selected genes, according to categorical differences of both
disease and pregnancy status were compared using the unpaired
t-test, whereas comparisons of transcript levels at different time
points were performed using the paired t-test. Two-way ANOVA
was used to examine the effects of both disease and pregnancy on
transcripts. All p-values were based on two-tailed statistical tests,
with a significance level of 0.05.
Results
GeneChip Array
MS signature. Feature selection of transcripts characterizing
MS was done comparing transcription profiles of MS patients vs.
healthy controls, before pregnancy. A total of 404 transcripts was
shown to be differentially expressed in patients as compared to
healthy controls (pfp#0.05) (Figure 1A, Table S1). Of these, 347
transcripts were considered the most discriminant gene-set by
PAMR analysis (Table 3) [23].
Principle components analysis (PCA) on the pre-selected genes
revealed a clear separation between healthy donors and MS
patients (Figure 1B).
Changes in the MS signature occurring during
pregnancy. Upon entering the second step of the analysis, we
evaluated what changes in expression are detected in the MS
signature, when nine months pregnant MS patients are compared
with nine months pregnant healthy controls. Interestingly, during
gestation the MS signature lost its discrimination power (Table 2).
This agreed with the normalization of the MS phenotype during
pregnancy. However, the event might be due to an experimental
statistical power issue, and thus a validation on a larger cohort of
patients was needed. On this ground, we have detected the
transcripts displaying the most pronounced discrimination changes
during pregnancy and subsequently performed an extended real
time RT-PCR validation on these transcripts.
An arbitrary ICC threshold of 0.4 was used to detect transcripts
that did not respond in a similar way in the two experimental
conditions and therefore were associated with not only pregnancy,
but also MS disease [24]. This analysis identified eight transcripts
that displayed the most pronounced change during pregnancy as
defined by an ICC,0.4. The eight transcripts included suppressor
of cytokine signaling-2 (SOCS2), tumor necrosis factor alpha-
induced protein-3 (TNFAIP3), nuclear receptor subfamily-4
member-2 (NR4A2), CXC chemokine receptor-4 (CxCR4), zinc-
finger protein-36 C3H type-like-1 (ZFP36L1), polymerase (RNA)
II polypeptide J (POLR2J), family with sequence similarity-49
member-B (FAM49B), and the stromal antigen-3 like-1
(STAG3L1).
Real Time RT-PCR Data
Validation of selected transcripts. Genes of interest were
measured and directly validated by quantitative real time RT-
PCR using the same patients and healthy controls’ samples as
tested by microarray. A further validation of the expression
profiles was performed by using blood samples from an
independent group of both MS patients and healthy controls
followed during their pregnancy. In both validation processes, real
time RT-PCR profiles agreed with microarray profiles for seven of
the eight transcripts. Particularly, before pregnancy TNFAIP3,
NR4A2, SOCS2, and CxCR4 were down-regulated in MS
patients respect to healthy controls (all p#0.0001). On the
contrary, POLR2J, STAG3L1, and FAM49B were up-regulated
in MS patients with respect to healthy controls (all p#0.0033)
(Figure 2).
Longitudinal analysis. As shown by longitudinal analysis,
the overall deregulation of gene expression reverted to ‘‘normal’’
during gestation; specifically, pregnancy was shown to revert the
imbalance already within the third month of gestation (all p=NS).
On the contrary, in the post-partum gene expressions rebounded
to levels which were significantly different between MS patients
and healthy controls (all p#0.01) and similar to the pre-pregnancy
levels (Figure 2A–G). Clearly, since the time span of collection of
the post-partum samples stretches over several months,
corresponding results should be viewed carefully and variability
should be taken into account.
Considering both validation processes, PCR results for
ZFP36L1 did not agree with those indicated by microarray, as
this latter transcript did not show differences in expression before
pregnancy, and no pregnancy-related regulation was evident
(Figure 2H).
Two-way ANOVA was used to determine the effects of MS
disease and pregnancy for gene expression levels. The idea is that
both MS disease and pregnancy might affect the gene expression.
Results showed that the individual effect on gene expression of
both pregnancy and MS disease could not be measured for
CxCR4, TNFAIP3, NR4A2, and FAM49B, even though
parameter effect was observed on their own (all p$0.080). For
these genes it was clear that both disease and pregnancy have a
different effect at different time points: when the progress of
pregnancy is decreasing gene expression in healthy controls, the
disease status increases that same gene expression, at the same
time point. Therefore both effects annihilated each other, but an
interaction between pregnancy and disease status was found to be
significant (p#0.021). Differently, pregnancy had a large effect on
SOCS2 and STAG3L1 gene expression (both p#0.0158), but not
the disease status (both p$0.1540). However, since pregnancy
seemed to have different effect between healthy controls and MS
patients, we concluded that there was interaction between disease
and pregnancy.
Finally, two-way ANOVA revealed a significant effect of both
pregnancy (p#0.0001) and MS disease (p#0.0001) with no
significant interaction (p=0.060) on the expression of POLJ2R.
Clinical analysis. To explore whether the seven validated
genes have any clinical relevance, we compared the expression
profiles of MS patients relapsing during pregnancy with those of
relapse-free patients. Six (18.7%) of the overall 32 MS patients had
a relapse during pregnancy, prevailing in the first trimester; a
Pregnancy in MS
PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8962Figure 1. Microarray analysis of blood mRNAs from MS patients and normal controls before pregnancy. (A) Supervised clustering of the
347 most discriminating transcripts (i.e. 404 probe sets), that were defined as ‘‘MS signature’’. Up-regulated genes are indicated by a red color, down-
regulated by a green color and genes that show no differences in expression are indicated in black. Patients are indicated as MS, while healthy
controls are indicated as N. (B) Principle Components Analysis (PCA) of the probe sets discriminating between 7 MS patients (close circles) and 9
healthy controls (i.e. 5 women who thereafter became pregnant +4 women who did not become pregnant) (open circles) before pregnancy. (C)
Microarray heat map plot depicting expression changes of the set of eight transcripts, within the ‘‘MS signature’’, whose expression was found to
change most significantly during pregnancy.
doi:10.1371/journal.pone.0008962.g001
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respectively. Interestingly, in relapse-free patients the imbalance
was reverted within the third month of gestation, whereas in
patients who had a relapse during pregnancy, the gene expression
imbalance was reverted later during gestation, i.e. at sixth month.
Particularly, delayed reversal of expression profiles was observed
for CxCR4, TNFAIP3, SOCS2, NR4A2, and POLR2J (Figure 3).
Two-way ANOVA showed that pregnancy had a large effect on
both FAM49B and STAG3L1 expressions (% of total variation
$16.45, both p#0.0002), but not the relapse (% of total variation
#1.50, both p$0.168). On the contrary, on TNFAIP3 and
CxCR4 expression, relapse had a quite significant effect (% of total
variation $3.30, p#0.050), but not pregnancy (% of total variation
#1.57, both p$0.6). Finally, both relapse and pregnancy showed a
similar effect on POLJ2R transcript (% of total variation =7.42
and 21.65, respectively; both p#0.0007), without interaction.
Individual effect on gene expression of both pregnancy and
relapse could not be measured for NR4A2 and SOCS2 (all
p$0.172).
Protein Expression
In order to confirm the gene expression results on the protein
level, we compared the mRNA levels to CxCR4, SOCS2 and
TNFAIP3 protein expression measured by western blot on the
same samples obtained from 6 MS patients and 3 healthy controls,
followed during their pregnancy. For the three genes, significant
correlations were found between mRNA results and protein
amounts. Particularly, we found that, similar to mRNA transcripts,
before pregnancy TNFAIP3, SOCS2, and CxCR4 protein level
were down-regulated in MS patients respect to healthy controls (all
p#0.004), while the overall deregulation of protein expression
reverted to ‘‘normal’’ during gestation (Figure 4).
Discussion
In order to identify modulated gene expression patterns, which
correlate with the beneficial effect of pregnancy on disease course
in MS, we undertook a genomic approach in profiling the genes
expressed in PBMCs of MS patients and healthy volunteers,
before, during, and after pregnancy.
First, a gene expression-based signature of MS was defined
using genome-wide gene expression profiling. Of the 14564 genes
on the array, 347 genes were found to have significantly altered
expression in non-pregnant MS patients with respect to non-
pregnant healthy controls. Since the MS phenotype seems to
revert to a normal phenotype during pregnancy, we have then
evaluated what changes in expression are detected in the MS
signature, when nine months pregnant MS patients are compared
with nine months pregnant healthy controls. Interestingly,
pregnancy resulted in the reversion of the MS-related expression
profile, as during pregnancy the MS signature lost its discrimina-
tion power. Longitudinal analysis showed that the overall
deregulation of gene expression reverted to ‘‘normal’’ already
within the third month of gestation, while during the post-partum
gene expressions rebounded to levels which were similar to the
pre-pregnancy levels and thus significantly different between MS
patients and healthy controls.
Eight transcripts, within the initial MS signature, displayed the
most pronounced change during pregnancy. These transcripts
included SOCS2, TNFAIP3, NR4A2, CxCR4, ZFP36L1,
POLR2J, FAM49B, and STAG3L1. Data were also corroborat-
ed by quantitative real time RT-PCR, showing discordance for
only one transcript, i.e. ZFP36L1. For this transcript, microarray
results indicated a pregnancy-related regulation, while real time
RT-PCR revealed no changes in expression across the experi-
mental conditions. Interestingly, all of the validated transcripts,
with the exception of FAM49B and STAG3L1, which are genes
encoding proteins of as yet unknown function, have been
previously reported to be associated with MS and other
autoimmune diseases [25–31]. These transcripts indeed, regulate
several important inflammatory processes: TNFAIP3 is critical in
limiting inflammation by terminating TNF-induced NFkB
responses [32], NR4A2 has an important role in mediating
multiple inflammatory signals [30,33,34], SOCS2 inhibits signal
transduction induced by several cytokines including IL-6 [29,35],
CxCR4 plays a crucial role in the trafficking of Treg cells [36,37],
and POLR2J is deregulated in some inflammatory diseases [25].
The involvement of inflammation-related genes in both preg-
nancy and MS outcome seems likely, as a regulation of
inflammation is supportive for successful reproduction, and also
positively influences MS [9–13]. Notably, we found expression
profiles which were in line with the inflammatory nature of MS in
non-pregnant MS patients, as well as with the anti-inflammatory
milieu observed during pregnancy. Moreover, it is noteworthy
that most of these transcripts have been reported to be regulated
by estrogenic hormones [38–40], thus strengthening the main
immunological mechanisms of adaptation of the maternal
immune system during pregnancy.
Another interesting feature of our data derives from the
observation that gene expression profiles correlated with the
clinical outcome in MS patients. Indeed, MS patients relapsing
during pregnancy showed different expression profiles when
compared to relapse-free patients, as they displayed delayed
reversal of expression, namely at month six or nine, compared to
Table 3. Cross-validation of the MS signature by the PAMR (Prediction Analysis for Microarrays) method in A) non-pregnant
women and B) 9 months pregnant women.
PAMR cross classification results on non-pregnant women. MS patients Normal controls Class Error rate
MS patients 70 0 %
Normal controls 08 0 %
Overall error rate =0.0
PAMR cross classification results on 9 months pregnant women. MS patients Normal controls Class Error rate
MS patients 43 4 3 %
Normal controls 13 2 5 %
Overall error rate =0.34
doi:10.1371/journal.pone.0008962.t003
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PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8962Figure 2. Average gene expression profiles in the overall cohort of MS patients and healthy controls. Comparison of average profiles of
(A) CxCR4, (B) TNFAIP3, (C) SOCS2, (D) NR4A2, (E) FAM49B, (F) POLR2J, (G) STAG3L1, and (H) ZFP36L1 gene expressions in peripheral blood
mononuclear cells obtained from 16 healthy controls (open columns) and 32 patients with multiple sclerosis (filled columns), followed during their
pregnancy. Seven expression profiles from real time RT-PCR showed trends that agreed with the previous microarray profiles (A-G), while a single PCR
results (i.e. ZFP36L1) (H) did not agree with that indicated by microarray: this gene showed no pregnancy-related regulation. Mean and bidirectional
standard deviation values are indicated. The influence on the gene expressions of the time span between post-partum sample collection and delivery
is comparable with the higher standard deviations observed for the latter time point.
doi:10.1371/journal.pone.0008962.g002
Pregnancy in MS
PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8962Figure 3. Average gene expressions in the overall cohorts of healthy controls and MS patients, subdivided based on their clinical
outcome. Real time RT-PCR comparison of the average profiles of (A) CxCR4, (B) TNFAIP3, (C) SOCS2, (D) NR4A2, (E) FAM49B, (F) POLR2J, and (G)
STAG3L1 gene expressions in peripheral blood mononuclear cells, obtained from 16 healthy controls and 32 patients with multiple sclerosis. MS
patients were subdivided based on their clinical outcome, i.e. expression profiles of MS patients relapsing during pregnancy (triangles, n=6) were
compared with those of relapse-free patients (circles, n=26) and healthy controls (squares, n=16). Mean and bidirectional standard deviation values
are indicated.
doi:10.1371/journal.pone.0008962.g003
Pregnancy in MS
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for the five above mentioned inflammation-related genes.
While on one side the present study shows an early pregnancy-
induced up-regulation of the CxCR4, TNFAIP3, SOCS2, and
NR4A2 transcripts in MS patients, on the other side data reveal a
pregnancy-related down-regulation of the same genes, in healthy
controls, as well as in MS patients after the achievement of a
healthy gene expression profile. These reductions in expression
observed during gestation correlate with the respective role of the
genes in pregnancy: SOCS2 negatively regulates growth hormone
action and inhibits prolactin signal transduction [41], thus its
down-regulation is important for a successful pregnancy. Likewise,
TNFAIP3 is involved in trophoblast invasion and its expression is
physiologic in early pregnancy, but its up-regulation in later
pregnancy augurs poorly [42]. Regarding CxCR4, a similar down-
regulation was seen in the early placental tissue as compared to the
term from healthy women [43]. This late down-regulation strongly
suggests that CxCR4 has a role in the earlier part of pregnancy,
when embryogenesis and much of the organogenesis takes
place.
As regarding the NR4A2 transcript, at first glance its expression
contradicts earlier works where NR4A2 was shown to be up-
regulated in MS patients with respect to healthy controls [28,29].
However, the difference may be explicable in terms of different
experimental conditions: in the previous study, expression profiling
was performed in specific cell type (i.e. T cells), whereas PBMCs,
as used here, include various cell subtypes. Furthermore, the
present study analyzed patients with no active MS before
enrolment, while previous work included clinically different
patients [44]. On the other hand, recent studies demonstrated a
potent anti-inflammatory activity of NR4A2 in microglia and
astrocytes, showing that quantitative defects in the expression or
activities of this protein could predispose certain organ systems to
inflammation-sensitive pathologies [33–34].
Figure 4. Protein expression of the CxCR4, SOCS2, and TNFAIP3 genes. Representative western blot bands of (A) CxCR4, (B) SOCS2, and (C)
TNFAIP3 in PBMCs of a healthy control (blood sample taken before pregnancy) and a MS patient (blood samples taken before and during pregnancy).
Corresponding b-Actin bands as loading control are shown in the upper panels. The lower panels in A–C show quantification of the western blot
analysis for the respective protein. Particularly, the panels show the comparison of average profiles (with standard deviations) of (A) CxCR4, (B) SOCS2,
(C) TNFAIP3 protein expressions in PBMCs obtained from 3 healthy controls (open columns) and 6 patients with multiple sclerosis (filled columns),
followed during their pregnancy.
doi:10.1371/journal.pone.0008962.g004
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of the changes in expression noted reflect a shift in the relative
distributions of different subpopulations rather than real changes
in gene expression. Although this is unlikely to be the case for
molecules such as CxCR4, SOCS2, TNFAIP3 which are almost
universally expressed by blood cells in response to inflammation, it
could account for some of the apparent changes in expression of
genes known to be highly expressed by specific cell types, e.g.
NR4A2, which is mainly expressed by myeloid cells [45].
Nevertheless, although further studies on PBMCs subsets are
logically needed, it is notable that presented changes are associated
with a decrease in disease activity assessed by the occurrence of
relapses during pregnancy. Hence, although limited by the low
number of subjects, this is the first study in which the pregnancy-
related decrease in disease activity of MS is investigated at a
transcriptional level, a finding that broads our understanding of
the pathogenesis of MS and might prove useful for the
development of new therapeutic strategies.
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